Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
3.900
-0.230 (-5.57%)
Jan 15, 2026, 4:00 PM EST - Market closed
Precision BioSciences Employees
Precision BioSciences had 108 employees as of December 31, 2024. The number of employees decreased by 1 or -0.92% compared to the previous year.
Employees
108
Change (1Y)
-1
Growth (1Y)
-0.92%
Revenue / Employee
$6,463
Profits / Employee
-$774,093
Market Cap
93.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108 | -1 | -0.92% |
| Dec 31, 2023 | 109 | -89 | -44.95% |
| Dec 31, 2022 | 198 | 0 | - |
| Dec 31, 2021 | 198 | -33 | -14.29% |
| Dec 31, 2020 | 231 | 32 | 16.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DTIL News
- 3 days ago - Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire
- 18 days ago - Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 - Seeking Alpha
- 23 days ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Precision Biosciences: Still Swinging And Finally Drawing Blood - Seeking Alpha
- 2 months ago - Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 - Business Wire
- 2 months ago - Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript - Seeking Alpha
- 2 months ago - Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire
- 2 months ago - Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts - Business Wire